SEARCH OUR PAGES

Investors

Investors

Publications & information

Press Releases

Read more +

Corporate Presentation

Read more +

Regulated Information

Read more +

General Shareholders' Meetings

Read more +

Universal Registration Document

Read more +

Amendment to the 2020 Universal Registration Document

Download +

Semester financial report

Download +

Auditors' Report on Semester report 2021 (in French)

Download +

Live stock price

Click here for live stock price

Information

OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris

  • ISIN: FR0012127173
  • Ticker: OSE
  • Type of listing: continuous
  • Number of outstanding shares: 17,983,038 shares as of December 31, 2020
  • Eligible to Long-Only Deferred Settlement Service
  • Edison Jonas Peciulis

    E-MAIL
  • H.C. Wainwright & CO Swayampakula Ramakanth

    E-MAIL
  • Maxim Group Naureen Quibria, Ph.D

    E-MAIL
  • Rx Securities Joseph Hedden

    E-MAIL
  • Bryan, Garnier & Co Olga Smolentseva

    E-MAIL
  • Degroof Petercam David Seynnaeve

    E-MAIL
  • Gilbert Dupont Khalid Deojee

    E-MAIL
  • Invest Securities Jamila El Bougrini

    E-MAIL
  • Kepler Cheuvreux Pierre-Alexandre Desir

    E-MAIL
  • Portzamparc Christophe Dombu

    E-MAIL

Analyst Reports

2021

2020

2019

2018

2017

  • LifeSci Capital , June Read+
  • Aurgalys , May Read+
  • LifeSci Capital Initiation Report , February Read+
  • Kepler Cheuvreux Initiation note , February Read+
  • Aurgalys , January Read+

2016

All opinions, estimates or forecasts on the performance of OSE Immunotherapeutics are solely those of the analysts who issue them and do not in any way represent the opinions or forecasts of the Company or its management.